Tag: Nasdaq

NEW YORK - DFB Healthcare Acquisitions stockholders have voted to approve all of the proposals related to its merger with AdaptHealth Holdings. The company's board of directors previously approved the combination and recommended that stockholders do the same. Stockholders also approved proposals to: change DFB's name to AdaptHealth and remove certain provisions related to DFB's status as a blank check company; issue certain securities for complying with applicable listing rules of the Nasdaq Capital...

LANGHORNE, Pa. - Alliqua BioMedical, a provider of advanced wound care products, has raised $34.5 million through a public offering. The company, listed on the NASDAQ as ALOA, sold about 6.6 million shares of its common stock at a price of $4.55 per share. Alliqua plans to use the net proceeds from the offering to “fund the commercial expansion of its marketed products, to opportunistically pursue additional product platforms, and for working capital and general corporate purposes,” according...

GOLETA, Calif. - Inogen has received a notice from the NASDAQ stating it's not in compliance with a rule requiring timely filing of periodic financial reports with the Securities and Exchange Commission.Inogen received the notice on April 15 after failing to file its Form 10-K for the fiscal year ended Dec. 31, 2014, on two separate occasions.“The NASDAQ notice has no immediate effect on the listing or trading of Inogen's common stock on the NASDAQ Global Select Market,” the company stated...

MILWAUKEE - ARI Network Services, provider of data-driven software tools and marketing services, will ring the NASDAQ Stock Market's closing bell April 14. “Three years ago, we implemented a plan to return to NASDAQ, and today we are honored to commemorate the achievement of re-listing by formally ringing the closing bell,” said Roy Olivier, president and CEO. ARI has seen 10 consecutive years of positive EBITDA and operating cash flows, with 95% reoccurring revenue, according to a release.

GOLETA, Calif. - Inogen (INGN) opened for trading on the NASDAQ on Feb. 14, pricing about 4.4 million shares of its stock at $16 per share, the low end of an expected range of $16 to $18. On Feb. 18, the company's stock was trading at $15.28 per share. Inogen filed for an initial public offering (IPO) in November. J.P. Morgan was the sole bookrunner on the deal.

SAN DIEGO - ResMed will begin trading ex-dividends this Thursday on Feb. 14, according to an article from Nasdaq. Shareholders who purchased ResMed stock prior to the ex-dividend date are eligible for the cash dividend payment, which will be priced at $0.17 per share, and paid on March 19, 2013. This marks the third quarter ResMed has paid the same dividend, according to the article.

SAN DIEGO - ResMed CEO and Executive Chairman Peter Farrell sold 400,000 shares at an average price of $46.98 on Jan. 30, according to an article from Nasdaq.com. Farrell made the sale the same day CMS announced a reimbursement cut of, on average, 45% as part of Round 2 of competitive bidding, which drove ResMed's stock price to drop more than 6%.